BioGlue used for apical hemostasis during transapical TAVI may cause late sterile foreign body reactions requiring surgical debridement.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to possible late BioGlue reactions after transapical TAVI; case reports leave open causality and alternatives.
BioGlue (CryoLife Inc, Kenneswa, GA, USA), a bovine serum albumin-glutaraldehyde tissue sealant, was at times used to seal the myocardial holes of the polypropylene stitches at the apex of the heart during transapical aortic valve implantation (TAVI). We describe three patients who developed late wound healing problems after TAVI that were thought to be caused by BioGlue. The surgical wound revision was performed on the 115th, 41st and 60th days, respectively, after original TAVI procedures. At revision, a 'foreign body' reaction surrounded by healthy well-vascularized tissue was found. All intraoperative cultures were sterile despite evidence of purulent-like material at the time of wound debridement. The wounds healed 'per primam intentionem' and the patients' postoperative course was also completely uneventful.
No takes yet. Share an insight, caveat, or question.
Unbehaun et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: